OTOA

Summary

OTOA (otoancorin, HGNC:16378) is a protein-coding gene on chromosome 16p12.2, encoding Otoancorin (Q7RTW8). May act as an adhesion molecule.

The protein encoded by this gene is specifically expressed in the inner ear, and is located at the interface between the apical surface of the inner ear sensory epithelia and their overlying acellular gels. It is prposed that this protein is involved in the attachment of the inner ear acellular gels to the apical surface of the underlying nonsensory cells. Mutations in this gene are associated with autosomal recessive deafness type 22 (DFNB22). Alternatively spliced transcript variants encoding different isoforms have been found for this gene.

Source: NCBI Gene 146183 — RefSeq curated summary.

At a glance

• Gene–disease (curated): nonsyndromic genetic hearing loss (Definitive, ClinGen) — +2 more curated relationships
• GWAS associations: 1
• Clinical variants (ClinVar): 796 total — 57 pathogenic, 33 likely-pathogenic
• Phenotypes (HPO): 2
• Dosage sensitivity (ClinGen): haploinsufficiency autosomal recessive, triplosensitivity no evidence
• MANE Select transcript: NM_144672

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:16378
Approved symbol	OTOA
Name	otoancorin
Location	16p12.2
Locus type	gene with protein product
Status	Approved
Aliases	CT108
Ensembl gene	ENSG00000155719
Ensembl biotype	protein_coding
OMIM	607038
Entrez	146183

Gene structure

Transcript identifiers

Ensembl transcripts: 9 — 5 protein_coding, 2 retained_intron, 1 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000286149, ENST00000388956, ENST00000388957, ENST00000388958, ENST00000563506, ENST00000563871, ENST00000569064, ENST00000646100, ENST00000647277

RefSeq mRNA: 3 — MANE Select: NM_144672 NM_001161683, NM_144672, NM_170664

CCDS: CCDS10600, CCDS32403, CCDS53994

Canonical transcript exons

ENST00000646100 — 29 exons

Exon	Start	End
ENSE00001620241	21719387	21719504
ENSE00001621261	21697775	21697875
ENSE00001627233	21685230	21685361
ENSE00001627340	21719133	21719191
ENSE00001655532	21681738	21681825
ENSE00001656128	21691584	21691687
ENSE00001702377	21705169	21705292
ENSE00001717181	21679184	21679211
ENSE00001748269	21700888	21701027
ENSE00001754045	21687413	21687648
ENSE00001786904	21679036	21679066
ENSE00001804401	21678915	21678943
ENSE00003461045	21736261	21736390
ENSE00003462401	21752369	21752505
ENSE00003477917	21722905	21722978
ENSE00003481559	21751935	21752077
ENSE00003484059	21744881	21745036
ENSE00003558111	21716907	21717047
ENSE00003565000	21714985	21715152
ENSE00003574342	21728241	21728431
ENSE00003615926	21726523	21726658
ENSE00003640716	21730837	21730930
ENSE00003668917	21753027	21753124
ENSE00003672063	21757082	21757277
ENSE00003674219	21740721	21740908
ENSE00003688010	21709888	21710103
ENSE00003817826	21663968	21664232
ENSE00003824813	21678511	21678605
ENSE00003901178	21760470	21760729

Expression profiles

Bgee: expression breadth broad, 86 present calls, max score 78.53.

Top tissues by expression

109 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	78.53	gold quality
left testis	UBERON:0004533	69.42	gold quality
testis	UBERON:0000473	69.30	gold quality
right testis	UBERON:0004534	67.98	gold quality
adrenal tissue	UBERON:0018303	65.24	gold quality
spleen	UBERON:0002106	59.23	gold quality
prefrontal cortex	UBERON:0000451	57.23	gold quality
primary visual cortex	UBERON:0002436	54.75	gold quality
bone marrow	UBERON:0002371	54.54	gold quality
colonic epithelium	UBERON:0000397	53.75	gold quality
frontal cortex	UBERON:0001870	52.86	gold quality
bone marrow cell	CL:0002092	52.72	silver quality
lymph node	UBERON:0000029	51.21	gold quality
superior frontal gyrus	UBERON:0002661	50.87	gold quality
Brodmann (1909) area 9	UBERON:0013540	50.03	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	49.41	gold quality
cerebral cortex	UBERON:0000956	48.81	gold quality
anterior cingulate cortex	UBERON:0009835	48.79	gold quality
right adrenal gland cortex	UBERON:0035827	48.23	gold quality
monocyte	CL:0000576	48.13	silver quality
gall bladder	UBERON:0002110	47.57	gold quality
leukocyte	CL:0000738	47.52	silver quality
right frontal lobe	UBERON:0002810	46.76	gold quality
adrenal gland	UBERON:0002369	46.31	gold quality
liver	UBERON:0002107	45.82	gold quality
blood	UBERON:0000178	45.72	gold quality
placenta	UBERON:0001987	45.37	gold quality
muscle tissue	UBERON:0002385	44.97	silver quality
right coronary artery	UBERON:0001625	44.95	gold quality
left adrenal gland	UBERON:0001234	44.61	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 0.

Experiment	Marker?	Max mean expression
E-ANND-3	no	2.38

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

16 targeting OTOA, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-335-3P	99.93	73.36	4958
HSA-MIR-450B-5P	99.92	71.48	3175
HSA-MIR-153-5P	99.89	73.86	6317
HSA-MIR-944	99.82	70.85	3042
HSA-MIR-6752-3P	99.72	66.71	1587
HSA-MIR-18A-3P	99.56	65.68	1092
HSA-MIR-4643	99.49	67.63	1791
HSA-MIR-519A-2-5P	98.78	71.74	1401
HSA-MIR-520B-5P	98.78	71.74	1401
HSA-MIR-3922-5P	98.77	66.53	1059
HSA-MIR-4664-5P	98.17	65.07	1020
HSA-MIR-6819-5P	97.96	66.59	1071
HSA-MIR-7113-5P	97.88	67.33	1735
HSA-MIR-6737-5P	97.75	66.54	1044
HSA-MIR-6812-5P	97.56	65.39	1059
HSA-MIR-342-5P	97.25	64.10	817

Functional genomics

ClinGen dosage: haploinsufficiency 30 (autosomal recessive), triplosensitivity 0 (no evidence). ClinGen Gene Dosage Map

Literature-anchored findings (GeneRIF, showing 7)

• Large deletions in OTOA gene is associated with hearing loss. (PMID:19888295)
• A description of two novel OTOA mutations that were discovered in three consanguineous Pakistani families segregating autosomal recessive non-syndromic hearing impairment. (PMID:23173898)
• non-segregation of an OTOA p.Gln293Arg variant led to the discovery of a genomic microdeletion of OTOA on the opposite allele by copy number variation analysis. Overall, 13 pairs of recessive candidate variants were deemed causative in 13 patients. (PMID:29178603)
• the results of this reverse translational study confirmed GPI-anchorage of OTOA and showed that downstream sequences from the 589th amino acid are critical for GPI-anchorage. (PMID:30740825)
• Polymorphisms in Neuronal Growth Regulator 1 and Otoancorin Alternate the Susceptibility to Lung Cancer in Chinese Nonsmoking Females. (PMID:32552051)
• Molecular characterization of pathogenic OTOA gene conversions in hearing loss patients. (PMID:33492714)
• [Phenotype-genotype analysis of the autosomal recessive hereditary hearing loss caused by OTOA variations]. (PMID:37114731)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Otoa	ENSMUSG00000034990
rattus_norvegicus	Otoa	ENSRNOG00000017487

Paralogs (3): MSLN (ENSG00000102854), MSLNL (ENSG00000162006), STRC (ENSG00000242866)

Protein

Protein identifiers

Otoancorin — Q7RTW8 (reviewed: Q7RTW8)

All UniProt accessions (2): Q7RTW8, A0A2R8YG28

UniProt curated annotations — full annotation on UniProt →

Function. May act as an adhesion molecule.

Subcellular location. Apical cell membrane. Secreted. Extracellular space. Extracellular matrix.

Disease relevance. Deafness, autosomal recessive, 22 (DFNB22) [MIM:607039] A form of non-syndromic sensorineural hearing loss. Sensorineural deafness results from damage to the neural receptors of the inner ear, the nerve pathways to the brain, or the area of the brain that receives sound information. The disease is caused by variants affecting the gene represented in this entry.

Similarity. Belongs to the stereocilin family.

Isoforms (5)

UniProt ID	Names	Canonical?
Q7RTW8-1	1	yes
Q7RTW8-2	2
Q7RTW8-3	3
Q7RTW8-4	4
Q7RTW8-5	5

RefSeq proteins (3): NP_001155155, NP_653273, NP_733764 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026664	Stereocilin-rel	Family

UniProt features (25 total): glycosylation site 12, splice variant 7, signal peptide 1, chain 1, propeptide 1, sequence conflict 1, region of interest 1, lipid moiety-binding region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q7RTW8-F1	84.12	0.52

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (1): 1130

Glycosylation sites (12): 394, 398, 460, 544, 812, 911, 974, 156, 211, 244, 289, 321

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-163125	Post-translational modification: synthesis of GPI-anchored proteins

MSigDB gene sets: 51 (showing top): GSE45365_NK_CELL_VS_CD8_TCELL_UP, GOBP_SENSORY_PERCEPTION_OF_MECHANICAL_STIMULUS, GOBP_GROWTH, GOCC_CELL_SURFACE, GOBP_MULTICELLULAR_ORGANISM_GROWTH, BALLIF_DEVELOPMENTAL_DISABILITY_P16_P12_DELETION, GOCC_APICAL_PLASMA_MEMBRANE, GOBP_SENSORY_PERCEPTION, GOBP_CELL_SUBSTRATE_ADHESION, GOBP_CELL_MATRIX_ADHESION, GOCC_APICAL_PART_OF_CELL, chr16p12, GOCC_SIDE_OF_MEMBRANE, GOCC_PLASMA_MEMBRANE_REGION, GOBP_DEVELOPMENTAL_GROWTH

GO Biological Process (4): cell-matrix adhesion (GO:0007160), sensory perception of sound (GO:0007605), transmission of nerve impulse (GO:0019226), multicellular organism growth (GO:0035264)

GO Molecular Function (0):

GO Cellular Component (6): extracellular region (GO:0005576), plasma membrane (GO:0005886), cell surface (GO:0009986), apical plasma membrane (GO:0016324), side of membrane (GO:0098552), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Post-translational protein modification	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	4
membrane	2
cell-substrate adhesion	1
sensory perception of mechanical stimulus	1
action potential	1
cell communication	1
chemical synaptic transmission	1
nervous system process	1
multicellular organismal process	1
developmental growth	1
cell periphery	1
apical part of cell	1
plasma membrane region	1
leaflet of membrane bilayer	1

Protein interactions and networks

STRING

414 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
OTOA	OTOG	Q6ZRI0	955
OTOA	TECTA	O75443	930
OTOA	TECTB	Q96PL2	925
OTOA	MYO15A	Q9UKN7	697
OTOA	TMPRSS3	P57727	667
OTOA	OTOF	Q9HC10	663
OTOA	TMC1	Q8TDI8	642
OTOA	LOXHD1	Q8IVV2	629
OTOA	SLC26A4	O43511	629
OTOA	GJB2	P29033	620
OTOA	LHFPL5	Q8TAF8	602
OTOA	CDH23	Q9H251	595
OTOA	TMPRSS4	Q9NRS4	590
OTOA	GIPC3	Q8TF64	583
OTOA	TMIE	Q8NEW7	582
OTOA	TRIOBP	Q9H2D6	582

IntAct

7 interactions, top by confidence:

A	B	Type	Score
M		psi-mi:“MI:0914”(association)	0.350
ATG16L1	ESYT2	psi-mi:“MI:0914”(association)	0.350
OTOA	SLC27A2	psi-mi:“MI:0914”(association)	0.350
TEDC1	GMNN	psi-mi:“MI:0914”(association)	0.350
BTNL2	HSPA5	psi-mi:“MI:0914”(association)	0.350
PPM1M	HSPA8	psi-mi:“MI:0914”(association)	0.350

BioGRID (14): OTOA (Affinity Capture-MS), OTOA (Affinity Capture-MS), OTOA (Affinity Capture-MS), OTOA (Affinity Capture-MS), OTOA (Affinity Capture-MS), SLC27A2 (Affinity Capture-MS), GALNT1 (Affinity Capture-MS), OTOA (Affinity Capture-MS), OTOA (Affinity Capture-MS), HSPA5 (Affinity Capture-MS), HTATIP2 (Affinity Capture-MS), OTOA (Affinity Capture-MS), OTOA (Affinity Capture-MS), OTOA (Protein-peptide)

ESM2 similar proteins: A6NGW2, A6NHZ5, D3Z7H8, G7PWZ3, L5KLU7, O43157, O60486, Q03157, Q04912, Q0V8J4, Q13421, Q2HJE5, Q2PT31, Q3TYX2, Q3UH93, Q3V3V9, Q594P2, Q5EA85, Q5JZY3, Q61468, Q6F5E8, Q6MG64, Q6QNU9, Q76MJ5, Q7RTU9, Q7RTW8, Q7TN88, Q7TNJ2, Q7Z442, Q8BYG9, Q8C160, Q8C2S7, Q8CB67, Q8CJH3, Q8IUL8, Q8IZF5, Q8IZY2, Q8K4C2, Q8K561, Q8R2Q6

Diamond homologs: Q7RTW8, Q8K561, Q8VIM6

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

796 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	57
Likely pathogenic	33
Uncertain significance	225
Likely benign	365
Benign	59

Top pathogenic / likely-pathogenic (30)

Variant ID	HGVS	Classification
1185107	NM_144672.4(OTOA):c.1560_1563del (p.Phe521fs)	Pathogenic
1192296	NM_144672.4(OTOA):c.346C>T (p.Gln116Ter)	Pathogenic
1194317	NM_144672.4(OTOA):c.1221del (p.Glu408fs)	Pathogenic
1360264	NM_144672.4(OTOA):c.335del (p.Lys112fs)	Pathogenic
1451127	NM_144672.4(OTOA):c.877C>T (p.Gln293Ter)	Pathogenic
1459527	NC_000016.9:g.(?21689836)(21739772_?)del	Pathogenic
164814	NM_144672.3(OTOA):c.(?2302)(2431_?)del	Pathogenic
164824	NM_144672.4(OTOA):c.1688+1G>T	Pathogenic
1803696	NM_144672.4(OTOA):c.1537del (p.Ala513fs)	Pathogenic
1803697	NM_144672.4(OTOA):c.3292C>T (p.Gln1098Ter)	Pathogenic
2092615	NM_144672.4(OTOA):c.306del (p.Gln102fs)	Pathogenic
2582944	NM_144672.4(OTOA):c.400-2A>G	Pathogenic
2637815	NC_000016.9:g.(?21675288)(21772051_?)del	Pathogenic
2693921	NM_144672.4(OTOA):c.1501_1517del (p.Glu501fs)	Pathogenic
2694053	NM_144672.4(OTOA):c.556_559dup (p.Ser187fs)	Pathogenic
2697333	NM_144672.4(OTOA):c.124G>T (p.Glu42Ter)	Pathogenic
2713897	NM_144672.4(OTOA):c.1269G>A (p.Trp423Ter)	Pathogenic
2743614	NM_144672.4(OTOA):c.1462dup (p.Ala488fs)	Pathogenic
2748699	NM_144672.4(OTOA):c.826del (p.Ile276fs)	Pathogenic
2751397	NM_144672.4(OTOA):c.2069_2070del (p.Cys690fs)	Pathogenic
2764599	NM_144672.4(OTOA):c.1527_1530dup (p.Gln511fs)	Pathogenic
2766019	NM_144672.4(OTOA):c.2003del (p.Val668fs)	Pathogenic
2775542	NM_144672.4(OTOA):c.1950G>A (p.Trp650Ter)	Pathogenic
2800906	NM_144672.4(OTOA):c.71_72del (p.Thr24fs)	Pathogenic
2820890	NM_144672.4(OTOA):c.22_23del (p.Tyr8fs)	Pathogenic
2829472	NM_144672.4(OTOA):c.1610del (p.Lys537fs)	Pathogenic
2841727	NM_144672.4(OTOA):c.1810_1813del (p.Asn604fs)	Pathogenic
2850166	NM_144672.4(OTOA):c.746_747del (p.Ser249fs)	Pathogenic
2852478	NM_144672.4(OTOA):c.505del (p.Gln169fs)	Pathogenic
2863063	NM_144672.4(OTOA):c.2095del (p.Arg699fs)	Pathogenic

SpliceAI

4001 predictions. Top by Δscore:

Variant	Effect	Δscore
16:21681733:T:A	acceptor_gain	1.0000
16:21685202:ACC:A	acceptor_gain	1.0000
16:21685203:C:G	acceptor_gain	1.0000
16:21685204:C:A	acceptor_gain	1.0000
16:21685214:A:AG	acceptor_gain	1.0000
16:21685215:A:G	acceptor_gain	1.0000
16:21685216:C:G	acceptor_gain	1.0000
16:21685217:A:AG	acceptor_gain	1.0000
16:21685218:C:G	acceptor_gain	1.0000
16:21685223:A:G	acceptor_gain	1.0000
16:21685226:A:AG	acceptor_gain	1.0000
16:21685228:A:AC	acceptor_loss	1.0000
16:21685228:A:AG	acceptor_gain	1.0000
16:21685228:AG:A	acceptor_gain	1.0000
16:21685229:G:GA	acceptor_gain	1.0000
16:21685229:GG:G	acceptor_gain	1.0000
16:21685229:GGC:G	acceptor_gain	1.0000
16:21685229:GGCA:G	acceptor_gain	1.0000
16:21685353:G:GT	donor_gain	1.0000
16:21685357:GCTTG:G	donor_gain	1.0000
16:21685359:TTGG:T	donor_loss	1.0000
16:21685360:TGGT:T	donor_loss	1.0000
16:21685361:GGT:G	donor_loss	1.0000
16:21685363:T:A	donor_loss	1.0000
16:21685393:G:GT	donor_gain	1.0000
16:21687408:TTTAG:T	acceptor_loss	1.0000
16:21687409:TTA:T	acceptor_loss	1.0000
16:21687411:A:AG	acceptor_gain	1.0000
16:21687411:AG:A	acceptor_gain	1.0000
16:21687411:AGG:A	acceptor_loss	1.0000

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1000064445 (16:21758675 C>A), RS1000073696 (16:21707144 C>T), RS1000120868 (16:21719621 A>C,G,T), RS1000165816 (16:21676899 G>A), RS1000182669 (16:21720365 C>T), RS1000213672 (16:21679684 T>A,C), RS1000240433 (16:21686807 C>A,T), RS1000314491 (16:21686481 C>G,T), RS1000315038 (16:21669279 G>A,C,T), RS1000348962 (16:21686178 C>G), RS1000381634 (16:21727018 T>TG), RS1000390759 (16:21735249 G>A), RS1000513906 (16:21666664 G>A), RS1000533994 (16:21711957 A>C,G), RS1000597646 (16:21701189 A>G)

Disease associations

OMIM: gene MIM:607038 | disease phenotypes: MIM:607039, MIM:220290, MIM:607197, MIM:600974, MIM:276900, MIM:181500

GenCC curated gene-disease

Disease	Classification	Inheritance
nonsyndromic genetic hearing loss	Definitive	Autosomal recessive
autosomal recessive nonsyndromic hearing loss 22	Definitive	Autosomal recessive
hearing loss, autosomal recessive	Supportive	Autosomal recessive

ClinGen Gene-Disease Validity (1)

Expert-panel classifications — Definitive > Strong > Moderate > Limited > Disputed > Refuted.

Disease	Classification	Inheritance
nonsyndromic genetic hearing loss	Definitive	AR

Mondo (8): autosomal recessive nonsyndromic hearing loss 22 (MONDO:0011762), hearing loss, autosomal recessive (MONDO:0019588), autosomal recessive nonsyndromic hearing loss 7 (MONDO:0010967), hearing loss disorder (MONDO:0005365), Usher syndrome (MONDO:0019501), schizophrenia (MONDO:0005090), autosomal recessive nonsyndromic hearing loss 1A (MONDO:0009076), nonsyndromic genetic hearing loss (MONDO:0019497)

Orphanet (6): Rare autosomal dominant non-syndromic sensorineural deafness type DFNA (Orphanet:90635), Rare autosomal recessive non-syndromic sensorineural deafness type DFNB (Orphanet:90636), Rare genetic deafness (Orphanet:96210), Usher syndrome (Orphanet:886), Rare non-syndromic genetic deafness (Orphanet:87884), NON RARE IN EUROPE: Schizophrenia (Orphanet:3140)

HPO phenotypes

2 total (3 of 2 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000407	Sensorineural hearing impairment
HP:0100753	Schizophrenia

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST005411_7	Thrombin-activatable fibrinolysis inhibitor activation peptide	5.000000e-07

MeSH disease descriptors (7)

Descriptor	Name	Tree numbers
D034381	Hearing Loss	C09.218.458.341; C10.597.751.418.341; C23.888.592.763.393.341
D052245	Usher Syndromes	C09.218.458.341.186.500.500; C09.218.458.341.887.886; C10.597.751.418.341.186.500.500; C10.597.751.418.341.887.886; C10.597.751.941.162.625.500; C11.768.585.658.500.813; C11.966.075.375.500; C16.131.077.299.500; C16.320.290.684.500; C23.888.592.763.393.341.887.886
C564609	Deafness, Autosomal Recessive (supp.)
C567134	Deafness, Autosomal Recessive 1A (supp.)
C564633	Deafness, Autosomal Recessive 22 (supp.)
C563417	Deafness, Autosomal Recessive 7 (supp.)
C580334	Nonsyndromic Deafness (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

11 total (human), top 11 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Benzo(a)pyrene	affects methylation, increases expression, increases mutagenesis	4
Aflatoxin B1	increases expression, increases methylation	3
aristolochic acid I	increases expression	1
ethyl-p-hydroxybenzoate	decreases expression	1
sodium arsenite	increases expression	1
benzo(e)pyrene	increases methylation	1
CGP 52608	affects binding, increases reaction	1
Endosulfan	increases expression	1
Methapyrilene	increases methylation	1
Urethane	decreases expression	1
Cadmium Chloride	increases expression	1

Clinical trials (associated diseases)

301 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT00205881	PHASE4	COMPLETED	Bilateral Benefit in Adult Users of the HiRes 90K Bionic Ear System
NCT00331539	PHASE4	UNKNOWN	Relationship Between Auto NRT and Behavioural T & C Levels With the Nucleus Freedom Cochlear Implant
NCT00424307	PHASE4	UNKNOWN	Bilateral Cochlear Implant Benefit in Young Children
NCT00765635	PHASE4	COMPLETED	Chlorobutanol, Potassium Carbonate, and Irrigation in Cerumen Removal
NCT03321006	PHASE4	COMPLETED	Treating Hearing Loss to Improve Mood and Cognition in Older Adults
NCT01499901	PHASE3	WITHDRAWN	Comparison of the Bilateral Sequential and Simultaneous Cochlear Implantation in the Deaf Children
NCT02561091	PHASE3	COMPLETED	AM-111 in the Treatment of Acute Inner Ear Hearing Loss
NCT03331627	PHASE3	COMPLETED	Safety and Efficacy of STR001-IT and STR001-ER in Patients With SSHL
NCT05532657	PHASE3	ACTIVE_NOT_RECRUITING	ACHIEVE Brain Health Follow-Up Study
NCT00013455	PHASE2	COMPLETED	Quantifying Auditory Perceptual Learning Following Hearing Aid Fitting
NCT00323427	PHASE2	COMPLETED	Clinical Trial of the Living Well With Hearing Loss Workshop
NCT00552786	PHASE2	COMPLETED	Antioxidation Medication for Noise-induced Hearing Loss
NCT00802425	PHASE2	COMPLETED	Efficacy of AM-111 in Patients With Acute Sensorineural Hearing Loss
NCT01139281	PHASE2	COMPLETED	The Protective Effect of Ginkgo Biloba Extract on Cisplatin-induced Ototoxicity in Humans
NCT01451853	PHASE2	UNKNOWN	SPI-1005 for Prevention and Treatment of Chemotherapy Induced Hearing Loss
NCT01588925	PHASE2	COMPLETED	Hearing Preservation Using Dexamethasone and Hyaluronic Acid for Cochlear Implantation
NCT01773278	PHASE2	RECRUITING	Cholesterol and Antioxidant Treatment in Patients With Smith-Lemli-Opitz Syndrome (SLOS)
NCT02832128	PHASE2	COMPLETED	Evaluating Possible Improvement in Speech and Hearing Tests After 28 Days of Dosing of the Study Drug AUT00063 Compared to Placebo (QuicKfire)
NCT04915183	PHASE2	RECRUITING	Atorvastatin to Reduce Cisplatin-Induced Hearing Loss Among Individuals With Head and Neck Cancer
NCT05258773	PHASE2	COMPLETED	Evaluation of the Presence of SENS-401 in the Perilymph
NCT06340633	PHASE2	RECRUITING	SPI-1005 in Adults Receiving Cochlear Implant
NCT00582946	PHASE1	COMPLETED	Wide-Bandwidth Open Canal Hearing Aid For Better Multitalker Speech Understanding
NCT00584155	PHASE1	WITHDRAWN	Protection From Cisplatin Ototoxicity by Lactated Ringers
NCT01206829	PHASE1	UNKNOWN	Hearing Impairment, Cognitive Therapy and Coping
NCT01256229	PHASE1	COMPLETED	Outcomes In Children With Developmental Delay And Deafness
NCT01343394	PHASE1	WITHDRAWN	Safety of Autologous Human Umbilical Cord Blood Mononuclear Fraction to Treat Acquired Hearing Loss in Children
NCT01452607	PHASE1	COMPLETED	Study to Evaluate the Safety and Pharmacokinetics of SPI-1005
NCT02259595	PHASE1	COMPLETED	Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC
NCT04041440	PHASE1	COMPLETED	Speech Recognition Training in Children With Hearing Loss
NCT07218913	PHASE1	RECRUITING	Testing the Addition of Pedmark to Cisplatin Chemotherapy for Reducing Drug-Induced Ear Damage in Men With Stage II-III Metastatic Testicular Germ Cell Tumors
NCT01802190	Not specified	TERMINATED	Prevalence of POU4F3 and SLC17A8 Mutations
NCT00486577	PHASE2/PHASE3	COMPLETED	Chronic Electrical Stimulation of the Auditory Cortex for Intractable Tinnitus
NCT00789061	PHASE2/PHASE3	UNKNOWN	Applying Proton Pump Inhibitor to Prevent and Treat Acute Fluctuating Hearing Loss in Patients With SLC26A4 Mutation
NCT01423409	PHASE2/PHASE3	COMPLETED	Multicenter Trial Assessing an Innovative VAS of Pain Among Deaf People
NCT05786378	PHASE2/PHASE3	UNKNOWN	Assessment of The Efficacy of Intratympanic Platelet Rich Plasma for Treatment of Sensorineural Hearing Loss.
NCT01108601	PHASE1/PHASE2	UNKNOWN	Transtympanic Ringer’s Lactate for the Prevention of Cisplatin Ototoxicity
NCT01621256	PHASE1/PHASE2	COMPLETED	Efficacy, Safety, and Tolerability of Ancrod in Patients With Sudden Hearing Loss
NCT06370351	PHASE1/PHASE2	RECRUITING	A Phase I/II Clinical Trial with SENS-501 in Children Suffering from Severe to Profound Hearing Loss Due to Otoferlin (OTOF) Mutations
NCT06545175	PHASE1/PHASE2	RECRUITING	Intracochlear Application of VSF1.01 for the Reduction of Cochlear Implant Surgery Related Trauma
NCT07304024	PHASE1/PHASE2	RECRUITING	A Treatment for a Form of Age-Related Central Auditory Processing Disorder Consisting of Clemastine Fumarate Plus Engineered Sound